Halopemide

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Halopemide  纯度: 99.65%

Halopemide 是一种有效的磷脂酶 D (PLD) 抑制剂，对人 PLD1 和 PLD2 的 IC50 分别为 220 和 310 nM。Halopemide 是多巴胺受体拮抗剂，是一种精神药物。

Halopemide

Halopemide Chemical Structure

CAS No. : 59831-65-1

规格 价格 是否有货 数量
5 mg ￥6600 In-stock
10 mg ￥11200 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Halopemide 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • GPCR/G Protein Compound Library
  • Metabolism/Protease Compound Library
  • Neuronal Signaling Compound Library
  • Anti-Cancer Compound Library
  • Neurotransmitter Receptor Compound Library
  • Exosomes Compound Library
  • Neurodegenerative Disease-related Compound Library
  • Lipid Metabolism Compound Library

生物活性

Halopemide is a potent phospholipase D (PLD) inhibitor, with IC50s of 220 and 310 nM for human PLD1 and PLD2, respectively. Halopemid is a dopamine receptors antagonist, and acts a psychotropic agent[1][2].

IC50 & Target[1][2]

PLD1

220 nM (IC50)

PLD2

310 nM (IC50)

dopamine receptors

 

体外研究
(In Vitro)

Halopemide (1-2 μM; 21 day) affects calcification in transdifferentiated MOVAS cells[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

Halopemide (10 mg/kg; p.o.) induces dyskinesias in the majority of monkeys tested[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

416.88

Formula

C21H22ClFN4O2
CAS 号

59831-65-1
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
参考文献

  • [1]. Scott SA, et al. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol. 2009 Feb;5(2):108-17.

    [2]. Neale R, et al. Acute dyskinesias in monkeys elicited by halopemide, mezilamine and the “antidyskinetic” drugs, oxiperomide and tiapride. Psychopharmacology (Berl). 1981;75(3):254-7.

    [3]. Skafi N, et al. Phospholipase D: A new mediator during high phosphate-induced vascular calcification associated with chronic kidney disease. J Cell Physiol. 2019 Apr;234(4):4825-4839.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务